Maelstrom Research Staging | MIReCoV_MSB_2_to_4_weeks_postdose

MIReCoV_MSB_2_to_4_weeks_postdose_2

Networks -

Variables -

Associated study MIReCoV Contingency Table

Population

MIReCoV - MSB

The population is composed of individuals recruited independently by the Medical Sciences Building (MSB) at the University of Toronto in Toronto, Ontario. Participants receive two doses of the BNT1162b2 COVID-19 vaccine three months apart.

Selection Criteria

Newborns

Twins

Countries

Canada

Territory

Toronto

Ethnic Origin

Health Status

Participants are healthy adults who were not exposed to COVID-19 prior to enrollment.

Other Criteria

Participants must receive two doses of the BNT1162b2 COVID-19 vaccine three months apart.

Recruitment

Sources of recruitment

General population

General Population

Selected sample

Supplementary Information

Participants were independently recruited at the University of Toronto.

Number of Participants

Number of Participants

Number of Participants with Biological Samples

Supplementary Information about selection criteria

MSB-1 cohort: 27 participants

MSB-2 cohort: 36 participants

More info

Data Collection Event

MIReCoV - MSB - 2 to 4 weeks post-dose 2

Blood and saliva samples were collected.

More info

Collected Dataset / MIReCoV_MSB_2_to_4_weeks_postdose_2

MIReCoV_MSB_2_to_4_weeks_postdose_2

Population

MIReCoV - MSB

Data Collection Event

MIReCoV - MSB - 2 to 4 weeks post-dose 2

Files

Variables Classifications